- Reuters•8 minutes ago
Amgen Inc on Wednesday reported higher-than-expected second-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast. The company is on track to meet or exceed its long-term objectives, Chief Executive Robert Bradway said in a statement. Amgen said it now expects 2016 adjusted earnings per share of $11.10 to $11.40, up from its prior view of $10.85 to $11.20.
After hours: 169.55-1.13 (-0.66%) as of 5:27 PM EDT
|Bid||169.72 x 100|
|Ask||170.00 x 200|
|52wk Range||130.09 - 181.81|
|Day's Range||167.44 - 171.08|
|Avg Vol (3m)||2,837,088|
As of 4:00 PM EDT. Market closed.